Who are ZULRESSO®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zulresso, Onfi, Sonata, Prosom, Prazene, Pentothal.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zulresso.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ZULRESSO® — Competitive Intelligence Brief

ZULRESSO® (ZULRESSO®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator. Area: Neuroscience.

marketed Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator GABA-A receptor alpha-1/beta-2/gamma-2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

ZULRESSO® (ZULRESSO®) — Supernus Pharmaceuticals, Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ZULRESSO® TARGET	ZULRESSO®	Supernus Pharmaceuticals, Inc.	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
Onfi	CLOBAZAM	Lundbeck Pharms Llc	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	2011-01-01
Sonata	ZALEPLON	Pfizer	marketed	gamma-Aminobutyric Acid A Receptor Agonist [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1999-01-01
Prosom	ESTAZOLAM	Abbott	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1990-01-01
Prazene	PRAZEPAM	Parke Davis	marketed		GABA-A receptor alpha-1/beta-2/gamma-2	1982-01-01
Pentothal	THIOPENTAL	Abbott	marketed	thiopental	GABA-A receptor alpha-1/beta-2/gamma-2	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-09-05 — Onfi · 12403090 · Formulation · US
2039-09-05 — Onfi · 12290597 · Formulation · US
2040-01-31 — Onfi · 11541002 · Formulation · US

Sponsor landscape (Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class)

Sage Therap · 1 drug in this class
Supernus Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZULRESSO® — Competitive Intelligence Brief. https://druglandscape.com/ci/zulresso. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab